Key Highlights
- Shares of HIMS rallied approximately 13% on April 16, 2026, driven by FDA announcements regarding peptide regulatory evaluation
- FDA set advisory committee meetings for July 23-24 to assess multiple peptides for potential addition to the 503A Bulks List
- Bank of America Securities increased its price target from $21 to $25 while keeping its Neutral rating intact
- The bank views this development as a moderate long-term catalyst, without immediate effects on earnings projections
- Company insiders have divested roughly $3.4 million in shares over the last three months, recording no acquisitions
Shares of Hims & Hers Health (HIMS) experienced a significant rally, advancing as much as 13.72% on April 16, 2026, after regulatory authorities announced plans to convene advisory committee sessions to assess various wellness peptides that face current restrictions under existing guidance protocols.
Hims & Hers Health, Inc., HIMS
Regulatory officials released a formal notice establishing Pharmacy Compounding Advisory Committee sessions scheduled for July 23 and July 24. These sessions will examine multiple peptide-related bulk drug substances being considered for placement on the 503A Bulks List. This represents an initial procedural milestone rather than regulatory approval.
Public statements from RFK Jr. regarding potential shifts in FDA regulatory policy amplified investor optimism. Regulatory authorities are considering removing restrictions on as many as 12 peptides, with assessment timelines extending through February 2027.
The stock had already demonstrated strength before this announcement. During the preceding week, HIMS advanced roughly 25%, based on InvestingPro data.
Bank of America Increases Valuation Target
Bank of America Securities adjusted its outlook by elevating its price target on HIMS from $21 to $25, maintaining its Neutral rating. The investment bank raised its target valuation multiple to roughly 25.5 times from 21.5 times, referencing elevated peer multiples and peptide expansion possibilities.
Bank of America highlighted that this development could enable the company to redirect current GLP-1 compounding infrastructure toward alternative peptides. This consideration holds significance because HIMS has capital invested in GLP-1 infrastructure after previous FDA compounding limitations.
The investment bank exercised caution in its assessment. Analysts characterized this as “an initial small step” and indicated they anticipate no immediate influence on earnings forecasts pending formal regulatory decisions.
Regulatory authorities also emphasized that the majority of substances under evaluation continue to present potential safety concerns under existing guidance frameworks.
Additional HIMS Developments
HIMS recently integrated Novo Nordisk’s FDA-cleared GLP-1 medications onto its platform, featuring Wegovy in both injection and oral formulations. The Wegovy oral version represents the sole FDA-cleared GLP-1 weight management pill on the market.
The platform will additionally provide Ozempic injection pens, which carry FDA clearance exclusively for Type 2 diabetes management.
The GLP-1 marketplace has experienced intensifying competition. Amazon Pharmacy recently launched Eli Lilly’s newly cleared GLP-1 medication Foundayo with same-day delivery options, creating competitive pressure for both Novo Nordisk and HIMS.
Regarding insider activity, CFO Oluyemi Okupe submitted documentation to divest shares valued at roughly $4.9 million. During the previous three-month period, company insiders have sold approximately $3.4 million collectively, without any purchase transactions.
HIMS currently trades at a P/E multiple around 45-47x. According to InvestingPro’s assessment, the stock appears elevated compared to its Fair Value calculation. The company maintains a market capitalization of approximately $5.54 billion and serves more than 2 million subscribers.
Bank of America’s EBITDA projection for 2026 stands roughly 21% beneath Wall Street consensus figures, a variance the bank has noted in previous research communications.
